Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• Zilovertamab vedotin demonstrates plasma concentration changes over time in participants.
• The study measures plasma concentration of the antibody drug in patients with metastatic solid tumors.
• Participants received zilovertamab vedotin intravenously every three weeks for pharmacokinetic assessment.
• Findings suggest a need for further investigation into the drug's efficacy in metastatic solid tumors.